Home Featured Page 255

Featured

Latest

January 2025 Psychedelic Paten Update: Lykos’ New Continuation Applications; Ambio Files on Ibogaine & Magnesium

Microdosing, Psychedelic Science, and the Future of Mental Health with Paul Austin

A Crucible of Academia, Psychedelics, and Religion: Psychedelic Intersections 2025 at The Harvard Divinity School

UK Psychedelic Research Hindered by Red Tape, Experts Tell Lawmakers in Parliamentary Report

MDMA for Active-Duty Troops: Aaron Wolfgang on DoD’s Unprecedented Study

Octarine Bio announces closing of extended seed round financing of $1.2...

BetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using...

NeonMind Engages Certara to Advance its Synthetic Psilocybin Drug Candidates for...

DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a...

Nova Mentis Upgrades U.S. Listing to the OTCQB Venture Market

Group Ketamine-Assisted Psychotherapy: Practice and Promise of a New Frontier

Mydecine Innovations Group Announces Plans to Spin Out of its [U.S.]...

MindMed Increases Cash on Hand to CAD $205.2m (USD $162m), Closes...

The Pitfalls and Challenges of Psychedelic Medicine

Cybin Announces API Synthesis and Optimization of Multiple Tryptamine Derivatives and...

1...254255256...281 Page 255 of 281

January 2025 Psychedelic Paten Update: Lykos’ New Continuation Applications; Ambio Files...

Microdosing, Psychedelic Science, and the Future of Mental Health with Paul...

A Crucible of Academia, Psychedelics, and Religion: Psychedelic Intersections 2025 at...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.